Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng/ml

References

• Draisma G , BoerR, OttoSJet al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J. Natl. Cancer. Inst.95(12), 868–878 (2003).
   PubMed Web of Science ®Google Scholar
• Heijnsdijk EAM , WeverEM, AuvinenAet al. Quality-of-life effects of prostate-specific antigen screening. N. Engl. J. Med.367(7), 595–605 (2012).
   PubMed Web of Science ®Google Scholar
• Schroder FH , HugossonJ, RoobolMJet al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet384(9959), 2027–2035 (2014).
   PubMed Web of Science ®Google Scholar
• Carter HB , AlbertsenPC, BarryMJet al. Early detection of prostate cancer: AUA guideline. J. Urol.190(2), 419–426 (2013).
   PubMed Web of Science ®Google Scholar
• Ferro M , BuonerbaC, TerraccianoDet al. Biomarkers in localized prostate cancer. Future Oncol.12(3), 399–411 (2016).
   PubMed Web of Science ®Google Scholar
• Poyet C , NieboerD, BhindiBet al. Prostate cancer risk prediction using the novel versions of the European Randomised Study of Screening for Prostate Cancer (ERSPC) and prostate cancer prevention trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort. BJU Int.117(3), 401–408 (2016).
   PubMed Web of Science ®Google Scholar
• Spyropoulos E , KotsirisD, SpyropoulosKet al. Prostate cancer predictive simulation modelling, assessing the risk technique (PCP-SMART): introduction and initial clinical efficacy evaluation data presentation of a simple novel mathematical simulation modelling method, devised to predict the outcome of prostate biopsy on an individual basis. Clin. Genitourin. Cancer15(1), 129.e1–138.e1 (2017).
   Web of Science ®Google Scholar
• Porpiglia F , RussoF, ManfrediMet al. The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy? J. Urol. 192(1), 60–66 (2014).
   PubMed Web of Science ®Google Scholar
• Sreekumar A , PoissonLM, RajendiranTMet al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature457(7231), 910–914 (2009).
   PubMed Web of Science ®Google Scholar
• Lucarelli G , FanelliM, LaroccaAMet al. Serum sarcosine increases the accuracy of Prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml. Prostate72(15), 1611–1621 (2012).
   PubMed Web of Science ®Google Scholar
• Lucarelli G , RutiglianoM, GalleggianteVet al. Metabolomic profiling for the identification of novel diagnostic markers in Prostate cancer. Expert. Rev. Mol. Diagn.15(9), 1211–1224 (2015).
   PubMed Web of Science ®Google Scholar
• Maxim R , RomanciucF, CrisanNet al. LC–QTOF− ESI(+)/MS metabolomic profile analysis applied to identify blood biomarkers of benign hyperplasia and prostate cancer. Bulletin of UASVM Animal Science and Biotechnologies72(2), 173–181 (2015).
   Google Scholar
• Vickers AJ , CroninAM, AusGet al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the european randomized study of prostate cancer screening in Goteborg, Sweden. BMC Med.6, 19 (2008).
   PubMed Web of Science ®Google Scholar
• Guazzoni G , NavaL, LazzeriMet al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur. Urol.60(2), 214–222 (2011).
   PubMed Web of Science ®Google Scholar
• Hugosson J , CarlssonS. Overdetection in screening for prostate cancer. Curr. Opin. Urol.24, 256–263 (2014).
   PubMed Web of Science ®Google Scholar
• Schouten MG , van der LeestM, PokornyMet al. Why and where do we miss significant Prostate cancer with multi-parametric magnetic resonance imaging followed by magnetic resonance-guided and transrectal ultrasound-guided biopsy in biopsy-naïve men? Eur. Urol. pii: S0302-2838(16)30903-4, doi:10.1016/j.eururo.2016.12.006 (2017) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Klemann N , R⊘derMA, HelgstrandJTet al. Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study. Lancet Oncol. pii: S1470-2045(17)30025-6, doi:10.1016/S1470-2045(17)30025-6 (2017) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Ukimura O , ColemanJA, de la TailleAet al. Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur. Urol.63(2), 214–230 (2013).
   PubMed Web of Science ®Google Scholar
• Marshall S , TanejaS. Focal therapy for prostate cancer: the current status. Prostate Int.3(2), 35–41 (2015).
   PubMedGoogle Scholar
• Villers A , PuechP, MoutonD, LeroyX, BallereauC, LemaitreL. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical Prostatectomy findings. J. Urol.176(6), 2432–2437 (2006).
   PubMed Web of Science ®Google Scholar
• Schoots IG , RoobolMJ, NieboerD, BangmaCH, SteyerbergEW, HuninkMG. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared with standard transrectal ultrasound guided biopsy: a systematic review and meta-analysis. Eur. Urol.68(3), 438–450 (2015).
   PubMed Web of Science ®Google Scholar
• Mottet N , BellmuntJ, BollaMet al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur. Urol. pii: S0302-2838(16)30470-5, doi:10.1016/j.eururo.2016.08.003 (2016) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Ahmed HU , El-Shater BosailyA, BrownLCet al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. pii: S0140-6736(16)32401-1, doi: 10.1016/S0140-6736(16)32401-1 (2017) ( Epub ahead of print).
   Web of Science ®Google Scholar